Telesis Bio Statistics
Total Valuation
Telesis Bio has a market cap or net worth of 3.01 million. The enterprise value is 58.83 million.
Market Cap | 3.01M |
Enterprise Value | 58.83M |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
Earnings Date | Nov 8, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Telesis Bio has 1.77 million shares outstanding. The number of shares has increased by 2.24% in one year.
Shares Outstanding | 1.77M |
Shares Change (YoY) | +2.24% |
Shares Change (QoQ) | +3.54% |
Owned by Insiders (%) | 20.17% |
Owned by Institutions (%) | 3.16% |
Float | 612,106 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.15 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -1.13 |
EV / Sales | 3.01 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -2.58 |
Financial Position
The company has a current ratio of 1.89, with a Debt / Equity ratio of 3.57.
Current Ratio | 1.89 |
Quick Ratio | 1.44 |
Debt / Equity | 3.57 |
Debt / EBITDA | n/a |
Debt / FCF | -1.56 |
Interest Coverage | -16.20 |
Financial Efficiency
Return on equity (ROE) is -147.84% and return on invested capital (ROIC) is -29.41%.
Return on Equity (ROE) | -147.84% |
Return on Assets (ROA) | -26.52% |
Return on Capital (ROIC) | -29.41% |
Revenue Per Employee | 184,585 |
Profits Per Employee | -489,321 |
Employee Count | 147 |
Asset Turnover | 0.23 |
Inventory Turnover | 3.85 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.07% in the last 52 weeks. The beta is 1.76, so Telesis Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.76 |
52-Week Price Change | -89.07% |
50-Day Moving Average | 2.86 |
200-Day Moving Average | 5.06 |
Relative Strength Index (RSI) | 35.52 |
Average Volume (20 Days) | 62,725 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, Telesis Bio had revenue of 19.57 million and -51.87 million in losses. Loss per share was -30.82.
Revenue | 19.57M |
Gross Profit | 9.51M |
Operating Income | -35.48M |
Pretax Income | -48.78M |
Net Income | -51.87M |
EBITDA | -32.89M |
EBIT | -35.48M |
Loss Per Share | -30.82 |
Balance Sheet
The company has 10.21 million in cash and 35.55 million in debt, giving a net cash position of -25.34 million or -14.29 per share.
Cash & Cash Equivalents | 10.21M |
Total Debt | 35.55M |
Net Cash | -25.34M |
Net Cash Per Share | -14.29 |
Equity (Book Value) | 9.95M |
Book Value Per Share | -11.59 |
Working Capital | 7.14M |
Cash Flow
In the last 12 months, operating cash flow was -21.78 million and capital expenditures -1.01 million, giving a free cash flow of -22.79 million.
Operating Cash Flow | -21.78M |
Capital Expenditures | -1.01M |
Free Cash Flow | -22.79M |
FCF Per Share | -12.86 |
Margins
Gross margin is 48.60%, with operating and profit margins of -181.35% and -253.19%.
Gross Margin | 48.60% |
Operating Margin | -181.35% |
Pretax Margin | -249.29% |
Profit Margin | -253.19% |
EBITDA Margin | -168.09% |
EBIT Margin | -181.35% |
FCF Margin | -116.50% |
Dividends & Yields
Telesis Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.24% |
Shareholder Yield | -2.24% |
Earnings Yield | -1,812.76% |
FCF Yield | -756.27% |
Stock Splits
The last stock split was on May 9, 2024. It was a reverse split with a ratio of 0.0555556.
Last Split Date | May 9, 2024 |
Split Type | Reverse |
Split Ratio | 0.0555556 |
Scores
Telesis Bio has an Altman Z-Score of -6.26. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -6.26 |
Piotroski F-Score | n/a |